Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population
Stephen L. Chan(Chinese University of Hong Kong), Winnie Yeo(Chinese University of Hong Kong), Thomas W. T. Leung(Chinese University of Hong Kong), Giok S. Liem(Chinese University of Hong Kong), Philip J. Johnson(Prince of Wales Hospital), Tony Mok(Chinese University of Hong Kong), Ming C. Poon(Chinese University of Hong Kong), Anthony T.�C. Chan(Chinese University of Hong Kong), Brigette Ma(Chinese University of Hong Kong), Frankie Mo(Chinese University of Hong Kong), Tung Ching Chan(University of Washington), Paul B.S. Lai(Chinese University of Hong Kong)
Cited by 93
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k